This Administrative Core (A) supports the program entitled """"""""Developmental and Translational Pharmacology of Pediatric Antimicrobial Therapy"""""""" and is submitted as an application responsive to RFA-HD-10-026: Specialized Center in Research in Pediatric Developmental Pharmacology (RPDP) Program (U54). The overall theme of the proposed program at the UC, San Diego, is to bring together non-clinical and clinical experts in the fields of developmental physiology, pharmacology, and infectious diseases to advance the field of pediatric developmental pharmacology. This Administrative Core will serve as the central coordinating and communication focal point for the UC San Diego (RPDP) Center. It will support the 3 main Projects, the 2 initial and all future pilot projects as well as the other 3 program Cores. This Core will promote communication and overall cohesiveness among the various Cores and Project investigators of the RPDP to ensure efficient operations and cross-fertilization of ideas between basic and clinical investigators. It will organize all internal meetings, track financial status of the program and construct all program reports for the NIH. It will develop a database for current relevant literature citations and distribute them to the RPDP Center investigators. The Administrative Core will coordinate the solicitation and selection process for Pilot Projects. Finally, it will also serve as the focal point for interactions with the NIH and other supported RPDP Centers and will coordinate any cross training activities between UC San Diego's RPDP Center and other RPDP Centers. The Administrative Core it will play a critical role in the ensuring the success in the program.
Efficient organization, administration and communication is essential for overall RPDP Center success. This is particularly true due to the translational nature of the research where clinical and basic scientific investigator interactions may require additional nurturing and support.
|Kumaraswamy, Monika; Do, Carter; Sakoulas, George et al. (2018) Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies. Int J Antimicrob Agents 51:468-478|
|Choe, Donghui; Szubin, Richard; Dahesh, Samira et al. (2018) Genome-scale analysis of Methicillin-resistant Staphylococcus aureus USA300 reveals a tradeoff between pathogenesis and drug resistance. Sci Rep 8:2215|
|Sakoulas, George; Kumaraswamy, Monika; Kousha, Armin et al. (2017) Interaction of Antibiotics with Innate Host Defense Factors against Salmonella enterica Serotype Newport. mSphere 2:|
|Sakoulas, George; Rose, Warren; Berti, Andrew et al. (2017) Classical ?-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii. Antimicrob Agents Chemother 61:|
|Natale, Stephanie; Bradley, John; Nguyen, William Huy et al. (2017) Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. Pharmacotherapy 37:361-378|
|Sakoulas, George; Olson, Joshua; Yim, Juwon et al. (2016) Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 60:6609-6618|
|Lin, Leo; Kim, Janie; Chen, Hope et al. (2016) Component Analysis of Multipurpose Contact Lens Solutions To Enhance Activity against Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother 60:4259-63|
|Hollands, Andrew; Corriden, Ross; Gysler, Gabriela et al. (2016) Natural Product Anacardic Acid from Cashew Nut Shells Stimulates Neutrophil Extracellular Trap Production and Bactericidal Activity. J Biol Chem 291:13964-73|
|Shoji, Kensuke; Bradley, John S; Reed, Michael D et al. (2016) Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. Antimicrob Agents Chemother 60:2150-6|
|Lam, Lisa H; Capparelli, Edmund V; Kurzrock, Razelle (2016) Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol 78:427-32|
Showing the most recent 10 out of 71 publications